Bipartisan lawmakers urge FDA to close peptide loophole

A bipartisan group of lawmakers has urged the Food and Drug Administration to close a regulatory loophole that has allowed knockoff versions of retatrutide to enter the United States, according to a report published October 20 by STAT News. Retatrutide is an investigational obesity drug developed by Eli Lilly and has not received FDA approval for sale to the public.

Per STAT’s reporting, the loophole in question permits compounded or research-labeled versions of the drug to be imported and sold despite its unapproved status. The lawmakers’ letter to the FDA characterizes this pathway as a gap in oversight that allows unauthorized copies of the molecule to reach consumers outside the agency’s normal review and safety mechanisms.

STAT reports that the push comes amid broader scrutiny of compounding pharmacies and overseas suppliers that have capitalized on high demand for obesity treatments, producing versions of drugs still in clinical trials or pending approval. Eli Lilly’s retatrutide remains under investigation and has not completed the regulatory process required for general marketing.

The lawmakers’ letter calls on the FDA to take enforcement action to prevent further distribution of these unapproved versions. STAT’s account does not specify a timeline for the FDA’s response or detail what enforcement mechanisms the agency might deploy. The report identifies the group pressing the issue as spanning both political parties, though STAT’s summary does not name individual signatories or specify the letter’s exact demands beyond closing the cited loophole.